forex signal system trading: Bezos, Goldman, and Big Pharma All Back This Biotech

Below is an important message from one of our valued sponsors along with today's top headlines

Jeff Bezos, Goldman Sachs and a Big Pharma giant have invested billions into this stock - Ad

On August 23, 2018, this small biotech won a patent for a treatment that could help as many as 50 million people...and save the U.S. as much as $20 TRILLION. Jim Cramer says a drug like this would be "The Biggest Drug Ever." And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million. Learn More Here

Today's Top-Rated Analyst Stock!

Which analyst's stock recommendation should you trust? We've crunched the numbers and highlighted this analyst pick of the day. Learn More Here

URGENT BUY: 4 Hypergrowth Cryptos for 2021 - Ad

Matt McCall just released an urgent video detailing a rare setup in the crypto markets that could send four cryptos soaring. You can even get the name to one of them for free. Learn More Here

New Cannabis Products: PB & Pretzel Bites, CBD Topicals, Kush Queen's Tincture, Mini Pre-Rolls

As the cannabis market expands, it's hard to keep track of the many products that launch every week. But don’t worry, Benzinga always keeps you updated on the most interesting new cannabis products being launched. Learn More Here

CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS

by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address inflammatory, cancer and liver diseases, continues to expand its reach in the treatment of cancer, liver and inflammatory disease. Learn More Here

Penny Trades Now Available Thanks to SEC Loophole - Ad

Short term trading is FUN...and the gains can hit lightning fast. Warren Buffett made $12B with the idea behind this strategy. If you're thinking these are options, they're not! Learn More Here

How Does Change Healthcare's Debt Look?

Over the past three months, shares of Change Healthcare (NASDAQ:CHNG) increased by 1.72%. Before having a look at the importance of debt, let us look at how much debt Change Healthcare has. Learn More Here

Looking Into ContextLogic's Return On Capital Employed

During Q1, ContextLogic (NASDAQ:WISH) brought in sales totaling $772.00 million. However, earnings decreased 75.34%, resulting in a loss of $126.00 million. ContextLogic collected $794.00 million in revenue during Q4, but reported earnings showed a $511.00 million loss. Learn More Here

Analyzing Agnico Eagle Mines's Ex-Dividend Date

Agnico Eagle Mines (NYSE: AEM) declared a dividend payable on June 15, 2021 to its shareholders as of April 29, 2021. Learn More Here

Early Profit-Advantage On Wall Street's Hidden Uranium Stock - Ad

Uranium prices are soaring as more than HALF of global monthly uranium production has been taken offline as mines shut down amid the coronavirus pandemic. Investors are lining up for gains and it could be the windfall of a lifetime. The last time we saw something like this, the price of yellowcake roared all the way to $140. Well-timed investors could make 10X, 20X and even 30X gains! Learn More Here

Recap: Anaplan Q1 Earnings

Shares of Anaplan (NYSE:PLAN) decreased 1.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0.10), which missed the estimate of ($0.09). Learn More Here

Recap: Medtronic Q4 Earnings

Shares of Medtronic (NYSE:MDT) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 158.62% over the past year to $1.50, which beat the estimate of $1.42. Learn More Here

Information, charts or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. If you wish to no longer receive these offers click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only.We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Bezos, Goldman, and Big Pharma All Back This Biotech

No comments:

Post a Comment